Bipolar I disorder: Psychopathology, medical management and dental implications

Journal of the American Dental Association

Volumn 133, Issue 9, 2002, Pages 1209-1217

  Friedlander, Arthur H ^a   Friedlander, Ida K ^b   Marder, Stephen R ^c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b W Valley/Los Angeles Co Dept H   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM CARBONATE; TRANQUILIZER;

BIPOLAR DISORDER; DENTAL CARE; DENTAL CARIES; DRUG INTERACTION; HUMAN; PERIODONTAL DISEASE; PSYCHOLOGICAL ASPECT; REVIEW; UNITED STATES; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DENTAL CARE FOR CHRONICALLY ILL; DENTAL CARIES; DRUG INTERACTIONS; HUMANS; LITHIUM CARBONATE; PERIODONTAL DISEASES; UNITED STATES; XEROSTOMIA;

EID: 0036725221     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2002.0362     Document Type: Article

References (84)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: American Psychiatric Association; 1994:317-89.
2. McElroy SL, Keck PE Jr, Strakowski SM. Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996;57(supplement 3):14-26.
3. Sherwood Brown E, Suppes T, Adinoff B, Rajan Thomas N. Drug abuse and bipolar disorder: comorbidity or misdiagnosis? J Affect Disord 2001;65(2):105-15.
4. Montgomery DB. ECNP Consensus Meeting March 2000 Nice: guidelines for investigating efficacy in bipolar disorder. European College of Neuropsychopharmacology. Eur Neuropsychopharmacol 2001;11(1):79-88.
5. Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord 2001;3(4):181-8.
6. Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv 1999;50:201-13.
7. Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 1999;60(supplement 2):53-6.
8. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000;61(supplement 9): 97-104.
9. Murray CJ, Lopez AD. The global burden of disease: Summary. Cambridge, Mass.: Harvard School of Public Health; 1996.
10. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51(1):8-19.
11. Goldberg JF, Kocsis JH. Depression in the course of bipolar disorder. In: Goldberg JF, Harrow M, eds. Bipolar disorders. Washington: American Psychiatric Press; 1999:129-48.
12. Leibenluft E. Women and bipolar disorder: an update. Bull Menninger Clin 2000;64(1):5-17.
13. Zarate CA Jr, Tohen M, Baraibar G, Zarate SB, Baldessarini RJ. Shifts in hospital diagnostic frequencies: bipolar disorder subtypes, 1981-1993. J Affect Disord 1997;43(1):79-84.
14. Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000;48:573-81.
15. Sachs GS. A 25-year-old woman with bipolar disorder. JAMA 2001;285:454-62.
16. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58:844-50.
17. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999;50:1303-8.
18. Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate of new cases in 1998. Pharmacoeconomics 2001;19(5 Pt 1):483-95.
19. Meltzer HY. Genetics and etiology of schizophrenia and bipolar disorder. Biol Psychiatry 2000;47(3):171-3.
20. Huxley NA, Parikh SV, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harv Rev Psychiatry 2000;8(3):126-40.
21. Kupka RW, Nolen WA, Altshuler LL, et al. The Stanley Foundation Bipolar Network, 2: preliminary summary of demographics, course of illness and response to novel treatments. Br J Psychiatry 2001;178(supplement 41):S177-S83.
22. Gurling H, Smyth C, Kalsi G, et al. Linkage findings in bipolar disorder. Nat Genet 1995;10(1):8-9.
23. Papadimitriou GN, Dikeos DG, Karadima G, Avramopoulos D, Daskalopoulou EG, Stefanis CN. GABA-A receptor beta3 and alpha5 subunit gene cluster on chromosome 15q11-q13 and bipolar disorder: a genetic association study. Am J Med Genet 2001;105:317-20.
24. Manji HK, Lenox RH. The nature of bipolar disorder. J Clin Psychiatry 2000;61(supplement 13):42-57.
25. Strakowski SM, Del Bello MP, Adler C, Cecil DM, Sax KW. Neuroimaging in bipolar disorder. Bipolar Disord 2000;2(3 Pt 1):148-64.
26. Noga JT, Vladar K, Torrey EF. A volumetric magnetic resonance imaging study of monozygotic twins discordant for bipolar disorder. Psychiatry Res 2001;106(1):25-34.
27. Keck PE Jr, McElroy SL, Arnold LM. Bipolar disorder. Med Clin North Am 2001;85:645-61.
28. Brown ES, Bobadilla L, Rush AJ. Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. Bipolar Disord 2001;3(1):23-9.
29. Ferrier IN, MacMillan IC, Young AH. The search for the wandering thymostat: a review of some developments in bipolar disorder research. Br J Psychiatry 2001;178(supplement 41):S103-6.
30. Grunze H, Erfurth A, Amann B, Giupponi G, Kammerer C, Walden J. Intravenous valproate loading in acutely manic and depressed bipolar I patients. J Clin Psychopharmacol 1999;19:303-9.
31. Licht RW, Bysted M, Christensen H. Fixed-dosed risperidone in mania: an open experimental trial. Int Clin Psychopharmacol 2001;16(2):103-10.
32. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Doucherty JP. The Expert Consensus Guidelines Series: medication treatment of bipolar disorder 2000. Postgrad Med 2000 (special no):1-104.
33. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry 2000;48:593-604.
34. Sernyak MJ, Godleski LS, Griffin RA, Mazure CM, Woods SW. Chronic neuroleptic exposure in bipolar outpatients. J Clin Psychiatry 1997;58(5):193-5.
35. Levine J, Chengappa KN, Brar JS, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000;2(2):120-30.
36. Cookson J. Use of antipsychotic drugs and lithium in mania. Br J Psychiatry 2001;178(supplement 41):S148-56.
37. Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000;61:638-42.
38. Glick ID, Suppes T, DeBattista C, Hu RJ, Marder S. Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med 2001;134(1):47-60.
39. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001;35(3):187-91.
40. Schou M. Perspectives on lithium treatment of bipolar disorder: action, efficacy, effect on suicidal behavior. Bipolar Disord 1999;1(1): 5-10.
41. Bucht G, Smigan L, Wahlin A, Eriksson P. ECG changes during lithium therapy: a prospective study. Acta Med Scand 1984;216(1): 101-4.
42. Johannessen CU. Mechanisms of action of valproate: a commentary. Neurochem Int 2000;37(2-3):103-10.
43. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000;20(2):195-203.
44. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-9.
45. Ketter TA, Post RM. Clinical pharmacology in pharmacokinetics of carbamazepine. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in mood disorders. New York: Dekker; 1994:43-92.
46. Edwards JG, Anderson I, Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999;57:507-33.
47. Spigset O. Adverse reactions to selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999;20:277-87.
48. Goodnick PJ, Dominguez RA, DeVane CL, Bowden CL. Bupropion slow-release response in depression: diagnosis and biochemistry. Biol Psychiatry 1998;44:629-32.
49. Frances AJ, Kahn DA, Carpenter D, Docherty JP, Donovan SL. The expert consensus guidelines for treating depression in bipolar disorder. J Clin Psychiatry 1995;59(supplement 4):73-9.
50. Daly JJ, Prudic J, Devanand DP, et al. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord 2001;3(2):95-104.
51. Dubovsky SL. Electroconvulsive therapy. In: Kaplan HI, Sadock BJ, eds. Kaplan and Sadock's comprehensive textbook of psychiatry. 6th ed. Baltimore: Williams & Wilkins; 1995:2129-40.
52. Bailine SH, Rifkin A, Kayne E, et al. Comparison of bifrontal and bitemporal ECT for major depression. Am J Psychiatry 2000;157(1): 121-3.
53. Scott J. Cognitive therapy as an adjunct to medication in bipolar disorder. Br J Psychiatry 2001;178(supplement 41):S164-8.
54. Physicians' desk reference. 56th ed. Montvale, N.J.: Medical Economics; 2002.
55. McEvoy GK. AHFS drug information 2002. Bethesda, Md.: American Society of Health-System Pharmacists; 2002.
56. Madinier I, Berry N, Chichmanian RM. Drug-induced oral ulcerations (in French). Ann Med Interne (Paris) 2000;151:248-54.
57. Tritsaris K, Gromada J, Jorgensen TD, Nauntofte B, Dissing S. Reduction in the rate of inositol 1,4,5-trisphosphate synthesis in rate parotid acini by lithium. Arch Oral Biol 2001;46:365-73.
58. Amann B, Hummel B, Rall-Autenrieth H, Walden J, Grunze H. Bupropion-induced isolated impairment of sensory trigeminal nerve function. Int Clin Psychopharmacol 2000;15(2):115-6.
59. Friedlander AH. Lithium/bipolar disorder: their effects on salivary flow, dental caries and periodontal disease. In: Birch NJ, ed. Lithium: Inorganic pharmacology and psychiatric use - Proceedings of the Second British Lithium Congress, Wolverhampton, England, Sept. 6-9, 1987. Oxford, England: IRL Press; 1988:77-8.
60. Friedlander AH, Friedlander IK, Birch NJ. Prevalence of dental diseases among patients on long-term lithium therapy. In: Birch NJ, Padgham C, Hughes MS, eds. Lithium in medicine and biology. Carnforth, England: Marius Press; 1993;91-7.
61. Amsterdam JD, Settle RG, Doty RL, Abelman E, Winokur A. Taste and smell perception in depression. Biol Psychiatry 1987;22:1481-5.
62. Anttila SS, Knuuttila ML, Sakki TK. Depressive symptoms favor abundant growth of salivary lactobacilli. Psychosom Med 1999;61: 508-12.
63. Wallin MS, Rissanen AM. Food and mood: relationship between serotonin and affective disorders. Acta Psychiatr Scand 1994;377(supplement):36-40.
64. Christensen L, Somers S. Comparison of nutrient intake among depressed and nondepressed individuals. Int J Eat Disord 1996;20(1):105-9.
65. Chacko RC, Marsh BJ, Marmion J, Dworkin RJ, Telschow R. Lithium side effects in elderly bipolar outpatients. Hillside J Clin Psychiatry 1987;9(1):79-88.
66. Nemeroff CB. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 2000;61(supplement 13):19-25.
67. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001;62:486-91.
68. Elter JR, Beck JD, Slade GD, Offenbacher S. Etiologic models for incident periodontal attachment loss in older adults. J Clin Periodontol 1999;26(2):113-23.
69. Monteiro da Silva AM, Oakley DA, Newman HN, Nohl FS, Lloyd HM. Psychosocial factors and adult onset rapidly progressive periodontitis. J Clin Periodontol 1996;23:789-94.
70. da Silva AM, Newman HN, Oakley DA. Psychosocial factors in inflammatory periodontal disease: a review. J Clin Periodontol 1995;22:516-26.
71. Kurer JR, Watts TL, Weinman J, Gower DB. Psychological mood of regular dental attenders in relation to oral hygiene behaviour and gingival health. J Clin Periodontol 1995;22(1):52-5.
72. Corvin A, O'Mahony E, O'Regan M, et al. Cigarette smoking and psychotic symptoms in bipolar affective disorder. Br J Psychiatry 2001;179:35-8.
73. Haffajee AD, Socransky SS. Relationship of cigarette smoking to attachment level profiles. J Clin Periodontol 2001;28:283-95.
74. Krall EA, Garvey AJ, Garcia RI. Alveolar bone loss and tooth loss in male cigar and pipe smokers. JADA 1999;130(1):57-64.
75. Moss ME, Beck JD, Kaplan BH, et al. Exploratory case-control analysis of psychosocial factors and adult periodontitis. J Periodontol 1996;67(10 supplement):1060-9.
76. Schleifer SJ, Keller SE, Bartlett JA, Eckholdt HM, Delaney BR. Immunity in young adults with major depressive disorder. Am J Psychiatry 1996;153:477-82.
77. Kinane DF. Aetiology and pathogenesis of periodontal disease. Ann R Australas Coll Dent Surg 2000;15:42-50.
78. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998;32:692-8.
79. Wise M. Citalopram-induced bruxism. Br J Psychiatry 2001; 178:182.
80. Bostwick JM, Jaffee MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry 1999;60:857-60.
81. Hersh EV. Adverse drug interactions in dental practice: interactions involving antibiotics. JADA 1999;130:236-51.
82. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
83. Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics. JADA 1999;130:397-407.
84. Callahan AM, Marangell LB, Ketter TA. Evaluating the clinical significance of drug interactions: a systematic approach. Harv Rev Psychiatry 1996;4(3):153-8.